Abstract. Simian virus 40 (SV40) is known to be potently oncogenic and can induce several types of tumours, such as lymphoma. p53 was discovered as a cellular partner of the SV40 large T-antigen, the oncoprotein of this virus. There have not been many studies on SV40 and p53 in lymphomas and the ones that exist, are controversial. A comparison of these two components in lymphoma has not been reported previously. We exam ined 91 lymphomas [60 B-cell non-Hodgkin's lymphomas (B-NHLs), 19 B-cell acute lymphoblastic leukemias (B-ALLs), 7 B-cell precursor acute lymphoblastic leukemias and 5 T-cell acute lymphoblastic leukemias] for the presence of SV40. Overall, 40 samples from 12 B-NHL/19 B-ALL patients were additionally investigated for p53 mutation in the hot-spot exons 5 to 8. Overall, we found 62/91 lymphomas to be SV40-positive, among them 16/19 B-ALLs and 38/60 B-NHLs. SV40 was absent in 147 of the 149 blood control samples. We found 11 p53 mutations in 19 B-ALL patients: 5 in exon 5 (codons 132, 141, 143, 155 and 181), 4 in exon 7 (codons 236, 238 and 248), 2 in exon 8 (codon 273). In B-NHL patients we found p53-mutations in 9/12 samples: 6 of these in 3 lymph nodes (LNs). One LN harboured 3 different p53 mutations: Exon 5 (codon 132), exon 6 (codon 213) and exon 8 (codon 288). Another LN showed 2 different p53 mutations: Exon 6 (codon 213) and exon 8 (codon 285). Except for 1 nonsense mutation in an LN of a B-NHL patient, all 20 mutations were missense mutations, 2 were homozygous, both found in B-NHLsamples, and one of these (codon 175) is known to cause the global denaturation of p53. All occur in the DNA-binding domain of p53. All specimens showing a p53 mutation, were SV40-positive. p53 mutaions found in LNs of B-NHL patients harbour high SV40 copy numbers. Our data strongly support an important role for SV40, as well as a strong association of SV40 and p53 in childhood lympho-proliferative disorders.
Introduction
Lymphoma. Human malignant lymphomas encompass a wide spectrum of different lymphoproliferative disorders. Lymphoma is a transformation of either B or T cells or their subtypes. With about 210 new patients per year in Germany, lymphomas collectively rank third in frequency among childhood malignancies with a peak in incidence between 5-8 years of age, followed by a second larger peak in the mid-teens. B-cell lymphoma as well as B-cell acute lymphoblastic leukemia (B-ALL) are the most rapidly growing human cancers.
The most frequently recognized alterations are chromosomal translocations, deregulation of cytokine networks, immune suppression, activation of oncogene expression, and inactivation of tumour suppressor genes. Up to now, there have not been many studies on viral infections and lymphoma (1) , as these infections are aetiologically involved in these diseases.
It is known that p53 mutation is an important mechanistic step in the formation of diffuse large B-cell lymphomas (2) . p53 is frequently mutated in Burkitt's lymphoma cell lines (3) and an unusual p53 mutation was detected in Burkitt's lymphoma (4) . A recent study reported p53 mutations in circulating free DNA in patients with non-Hodgkin's lymphoma (NHL) (5) .
The pathogenesis of B-cell lymphomas is not yet well understood. An association between infectious agents and lymphoma development has been demonstrated for mucosaassociated lymphoid tissue (MALT) lymphomas of the stomach caused by Heliobacter pylori infection and persistent initial primary cutaneous B-cell lymphomas triggered by the Borrelia burgdorferi infection (6, 7) . Besides bacteria, viruses of the retrovirus and herpes families are possible aetiological agents of human leukaemias and lymphomas, so is Ebstein-Barr virus associated with Burkitt's lymphoma and Hodgkin's lymphoma and a viral cause has been postulated to increase the risk of NHLs in general (8) (9) (10) . The discovery of human herpes virus type 8 (HHV-8 or KSHV) has led to the identification of a rare and unusual group of virus-associated lymphoproliferative diseases (11) . Viral agents may contribute to the development of lymphomas by driving lymphoid cell proliferation or by inducing chronic antigenic stimulation (12, 13) . Individuals infected with the human immunodeficiency virus (HIV) are at great risk (60-to 200-fold) of developing lymphoma, although here the mechanism of lymphomagenesis is indirect (14) . Certain data suggest that hepatitis C virus infection is also associated with the increased incidence of lymphoma (15, 16) , whereas data relating lymphoma to Simian virus 40 (SV40), a highly oncogenic virus, remain rare. Nevertheless, SV40 could be taken into consideration for a putative role in human lymphomagenesis, alone or in combination with additional events, such as p53 mutation.
SV40. SV40 is a monkey virus that has been recognized as a contaminant of early polio vaccines provided to millions of individuals in Europe and the USA during mass vaccination between 1955 and 1963 (17-19) . The relevance of SV40 to human pathology was first reported in 1962 by Shein et al (20) who found that SV40 is able to infect and transform human and animal cells in vitro. This transforming activity mainly results from the interaction of the SV40 large-T-antigen with cellular proteins, one of which is p53 (21) . In 1972 it was reported for the first time, that SV40 induces leukaemia and lymphoma in hamster cells when inoculated systemically (22) . SV40 DNA oncogenecity is associated with the primary viral gene product, the large T-antigen (L-TAG), known to promote transformation by binding and inactivating tumour suppressor genes, such as p53 and pRb. Cells expressing L-TAG exhibit disrupted cell cycle progression, abnormal mitosis and aneuploidy.
Over the years, an increasing number of reports have suggested that SV40 causes specific tumour types, such as mesothelioma, brain and bone tumours. Few studies have shown the presence of SV40 in lymphomas (23) (24) (25) (26) (27) (28) (29) (30) (31) , and with contradicting results. Three studies (28, 32, 33) found about a 10, 13 and 14% incidence of SV40 in NHL, respectively, while 2 other studies (23,34) found a nearly identical higher incidence of SV40 in NHL (42 and 43%, respectively). Follow-up studies have not supported these findings (25, 29, 33, (35) (36) (37) (38) . MacKenzie et al failed to detect SV40 in a series of 152 NHLs even by using a highly sensitive TaqMan assay for SV40 detection, the same sensitive assay used in our investigation (29) . Capello et al similarly failed to detect consistent evidence of SV40 infection in 485 lymphoma specimens (36) . Other investigators have detected SV40 genomes in an intermediate proportion of cases (32, 37) . Using immunohistochemistry, Brousset et al did not detect evidence of SV40 L-TAG in any of the tumour cells of 232 NHL samples (39) . In contrast, Vilchez et al detected SV40 L-TAG in 12/55 HIV-associated lymphomas, although the viral antigen was detected in some but not all the tumour cells in an individual case (40) .
Most lymphoma studies based their detection of SV40 DNA on PCR, except that of MacKenzie et al (29) . One study which found no association of SV40 in any subtype of lymphoma of Spanish origin used virus-like-particle-based enzyme immunoassay with antibodies to SV40 (25) . The reasons for the discrepant findings are not clear. Technical factors, such as differences in assay sensitivity (41, 42) and the lack of specifity of large T-antibodies are possible explanations.
p53. The p53 protein was identified in 1979 as a cellular protein that forms a complex with the L-TAG of the oncogenic virus, SV40 (43, 44) . Since then, p53 has become conspicuous as a tumour suppressor and up to now the multifunctional p53 gene is the best studied gene involved in human cancer (45) (46) (47) (48) (49) . It is located on chromosome 17 (short arm, 17p13), a region that is frequently deleted in human cancer. The alteration or inactivation of p53 by mutation, or by its interaction with oncogenic products of DNA tumour viruses, can lead to cancers, such as childhood tumours and lymphoblastic malignancies (50) (51) (52) (53) (54) . Compared to other cancer types, haematological malignancies present a rather low incidence of genetic alterations in the p53 protein (10-20%), although the prognosis of patients with a mutation in the p53 gene is worse than those expressing the wild-type p53 protein (55) (56) (57) . Moreover, p53 mutations are predictors of poor survival in B-cell lymphomas as well of a high-risk group of patients diagnosised with follicular lymphoma (58) (59) (60) .
p53 mutations are the most common genetic changes in human cancer. The cell cycle is composed of a series of steps which can be negatively regulated by various factors. The p53 protein is the chief among the negative regulators. The p53 protein represses cell cycle proliferation and angiogenesis, and stimulates apoptosis mainly by acting as a transcription factor that controls the expression of genes whose gene products are involved in these processes (61) . p53 arrests cell cycle progression in the G1/S and G2 phases. G1/S phase arrest is obtained through the p53-mediated activation of the gene encoding the cyclin dependant kinase inhibitor p21. G2 arrest by p53 is less clear, but it may involve the effectors p21 (62) . The idea that the cellular p53 protein may be involved in the process of oncogenesis arose by virtue of its stable association with two different viral oncogenetic proteins, one of them SV40 L-TAG (63) (64) (65) (66) (67) . Therefore a cooperation between SV40 and p53 function can be discussed as a cooperation of p53 point mutations with activated ras oncogene, as has been done for colorectal carcinomas (68) . A recent report reflects on the common mechanism of transformation by small DNA viruses, such as SV40, and the inactivation of p53 (69) . Except for one report, correlating SV40 and p53 in diffuse large B-cell lymphoma in Tunesia (70) , such a correlation has not been studied as far as we know for childhood lymphoproliferative disorders. That study looked for the accumulation of p53 in the nucleus, not for p53 mutations, specifically.
In this study, we aimed to determine the prevalence and what role SV40 could play in lymphomas alone or in correlation with p53. Moreover, we aimed to obtain more information regarding the role of p53 in virally-associated or -infected tumours. Therefore, we investigated 91 cases of childhood lymphoproliferative malignancies and 151 control cases. In addition to conventional PCR and sequencing, we used the highly sensitive real-time PCR for the identification of SV40 in patient specimens. Till now, the latter is not a wide-spread method for the detection and identification of SV40, although we found this technique to be very appropriate for detecting and identifying, as well as for the quantification of SV40 in one step.
Moreover, we addressed the question of whether SV40 positivity correlates with p53 mutation in lymphomas, especially in B-ALLs, as well in B-NHLs. To our knowledge, a similar study on lymphomas has not been done up to now. This raises some very important questions, as L-TAG has a p53 binding site and is known to block p53 functions.
Materials and methods

Materials.
Fresh or frozen samples from bone marrow (BM) or peripheral blood (PB) from 91 children with lymphoproliferative disorders [19 B-ALLs, 7 B-cell precursor acute lymphoblastic leukemias (BCP-ALLs), 5 T-cell acute lymphoblastic leukemias (T-ALLs) and 60 B-NHLs] obtained at the time of diagnosis, containing between 50 and 90% malignant cells, as well as 149 fresh buffy coats from healthy German subjects derived from the blood transfusion centre, were analysed. The human fibroblast cell line, SV80, with multiple extra chromosomal SV40 copies and the African green monkey kidney cell line, COS-7, with one integrated SV40 copy, served as the positive controls. DNA derived from SV40-negative healthy subjects as well as DNA derived from normal bone served as the negative controls.
Isolation of viral and chromosomal DNA. Genomic DNA was extracted from fresh or frozen cells using Qiagen spin columns (QIAamp DNA mini or midi kit; Qiagen, Hilden, Germany) following the 'blood and body fluid protocol', according to the recommendations of the supplier. This DNA extraction method is suitable for extracting chromosomal, as well as extrachromosomal, episomal DNA (71, 72) .
SV40-specific PCR. SV40-specific primers were adapted to the L-TAG region, previously proven to be very specific (33, 73) : SV5 (5'-TAG ATT CCA ACC TAT GGA ACT GA-3' , nt 4574-4552) and SV6 (5'-GGA AAG TCC TTG GGG TCT TCT ACC-3', nt 4402-4425) (73) (Fig. 1) . The amplification product is a 172 bp fragment, including the retinoblastoma (Rb) pocket-binding domain with no intron sequences of L-TAG. DNA polymerase reaction was carried out using the 'Promega-Core-Kit' with TagBead Hot Start polymerase in the presence of 2.5 mM MgCl 2 and 0.5 µM of each primer in a final volume of 100 µl. PCR reactions were performed as previously described (74) with an annealing temperature of 56˚C and 45 cycles. Amplification fragments were analysed on agarose gel electrophoresis, with ethidium bromide staining. SV40-positive fragments were cut out, purified, and verified by sequencing and real-time PCR , including one hybridization step simultaneously. (nt 4524-4542) with the internal TaqMan probe (TM-probe) 5'-AACCTGTTTTGCTCAGAAGAAATGCCA-3' (nt 4487-4514) labelled with FAM (6-carboxyfluorescin) at the 5' end and TAMRA (6-carboxytetramethylrhodamine) at the 3' end (TIB Molbiol, Berlin, Germany), were used. For conventional PCR, primers SV5 and SV6, previously described in detail, were used (74) (Fig. 1 ).
Real-time quantitative PCR (RQ-PCR
The quality of the DNA was tested by amplification of the β-globin gene. Only samples with C T values of 20±1 cycle were selected for quantification. RQ-PCR reaction was carried out as described previously with an annealing temperature of 60˚C (41) . SV40-positive cell line (COS-1) DNA was serial diluted in SV40-negative DNA to achieve equal amounts in each dilution sample (500 ng per reaction). RQ-PCR reactions were performed with 6 dilutions (10 -1 to 10 -6 ), an unrelated SV40-negative DNA control, a negative control and the sample of interest in triple. Selected samples were analysed by agarose gel electrophoresis, cut out and finally sequenced. p53 mutation analysis. p53 was screened for mutations in exon 5-8, the regions, harbouring somatic hot-spot mutations (75, 76) . In these sequences, encompassing exons 5 through 8, most of the evolutionarily conserved amino acids are concentrated. Therefore, mutation analysis has been confined principally to these exons. Mutations outside this region are rare. Forward and reverse sequencing was carried out for all samples. In the case of a mutation, this was verified by a second independent reaction.
Primer sequences were adapted from the ones described by Weyrer et al (77) and are summarized in Table I . PCR reaction was carried out according the protocol of Sturm et al (78) , with an initial denaturation at 94˚C for 5 min and a final extension of 7 min at 72˚C each. Annealing temperatures were 55˚C for exon 5a, 65˚C for exon 5b, 60˚C for exon 6 and 8, and 58˚C for exon 7 with a 20-sec annealing time for each. The reaction mixture contained 100 µmol/l of each primer, 1 mmol/l MgCl 2 (except for exon 7: 0,8 mmol/l MgCl 2 ), 1,5 U TaqDNA polymerase (Platinum Taq, Invitrogen) in a total volume of 50 µl. PCR fragments were analysed on agarose gel electrophoresis, with ethidium bromide staining, cut out, purified, and finally sequenced.
Sequencing. The SV40 and p53 PCR products were cut out of the agarose gel, purified and extracted on 'Ultrafree-DA' spin columns (Millipore, Eschborn, Germany) at 5000 x g for 10 min. Purified DNA (2 µl) was used to produce singlestranded marked DNA, necessary for sequencing (ABI PRISM BigDye Terminator Cycle Sequencing Ready Reaction Kit), with both the forward and reverse primers previously used for amplification. The cycle sequencing reaction was: A 95˚C denaturation for 30 sec, 30 sec annealing with the temperature announced previously for the selected primers, and a 60˚C elongation for 4 min, in a total of 35 cycles. Products were sequenced on the 3130-Genetic Analyser (Applied Biosystems). Sequence data were first analysed by visual inspection and then with SeqMan Pro (DNAstar Lasergene-8) for mutations and compared to reference sequences. p53 mutations found in patients were compared to the UMD p53 website (79) for certification.
Results
The aim of this study was to investigate whether SV40 is present in lymphoproliferative disorders in German children as well as to determine the spread of SV40 in normal German subjects. Moreover, we wanted to determine the mutation rate of p53 at the well-known hot-spot regions exons 5 to 8 and to correlate this with the prevalence of SV40 in lymphoma specimens to get a hint of whether SV40 and p53 are co-players in this malignancy. second analysis round by RQ-PCR. Data derived from SV40 analysis with conventional PCR with SV5/SV6-primers showed that 5 out of 19 B-ALL patients were SV40-negative, while 2 of these negative patients were SV40-positive in the second additional SV40 analysis with the more sensitive RQ-PCR method. At least 16 out of the 19 B-ALL patients showed SV40 positivity. From 9 B-ALL patients we analysed more than one sample: In addition to BM, PB at the time of diagnosis or BM after chemotherapy in clinical remission, were analysed for SV40. These PB samples were SV40-negative, while the corresponding BMs were positive. All BM samples taken after chemotherapy remained SV40-positive in the cases where the BM at the time of diagnosis was SV40-positive. All lymphoma samples were analysed by RQ-PCR. Overall, we found that 62/91 lymphoma patients were SV40-positive, and among these 16/19 B-ALLs, 6/7 BCP-ALLs, 2/5 T-ALLs and 38/60 B-NHLs. These 38 B-NHL patients harboured SV40 in 3/3 PB, 3/3 lymph nodes (LNs), 2/3 tumours and 2/6 ascite (Asc) samples. From 5 B-NHL patients we analysed different samples at the time of diagnosis as well as during the course of the disease. Samples inlcuded LNs, Ascs, BM and PB. From these 5 B-NHL patients all samples taken at the time of diagnosis (LN, BM and Asc) were SV40-positive, and in the case of LN, had a high SV40 copy number (100-1000 copies/500 ng DNA). Except for the Asc samples of 2 patients, all samples taken during the course of the disease of these 5 B-NHL patients, were SV40-positive.
Half of all the SV40-positive specimens from the 91 lymphomas analysed, harboured about ≤10 copies SV40 in 500 ng DNA. Sixteen SV40-positive specimens showed 100 to >1000 SV40 copies in 500 ng DNA. As the controls, we analysed 149 buffy coat samples from healthy blood donors. In the healthy population we found that only 2 out of 149 buffy coat samples were SV40-positive with <10 copies per 500 ng DNA. Examples are shown in Fig. 3A -D and all SV40 data are summarized in Table II. p53 mutation analysis. Overall, 28 samples derived from the 19 B-ALL patients, from BM samples as well as from blood at the time of diagnosis, were subjected to SV40 analysis and screened for p53 mutations. Overall, we found 11 p53 mutations in these B-ALL specimens: 5 in exon 5 (codons 132, 141, 143, 155 and 181), 4 in exon 7 [codon 236s (2x), 238 and 248], 2 in Fig. 4 and summarized in Table III . The location of the full-length p53 gene is shown in Fig. 5 .
--------------------------------------------------------------------
Additionally, 12 different samples derived from 5 B-NHL patients were investigated for p53 mutation analysis. We chose those B-NHL patients from which we had LN samples, or those from which we had taken more than one sample during the course of disease. In 12 B-NHL samples we found 9 p53 mutations, 6 of these in 3 LNs. One LN (patient 4) harboured 3 different p53 mutations at the same time in exon 5 (codon 132), exon 6 (codon 213), and exon 8 (codon 288). Another LN (patient 1) showed 2 different p53 mutations at the same time in exon 6 (codon 213), and exon 8 (codon 285). One LN of B-NHL patient 2 showed one mutation in exon 5 (codon 175). This was a homozygous mutation which is known to cause the global denaturation of p53. A second homozygous p53 mutation (exon 5, codon 176) was found in an Asc sample at the time of diagnosis in patient 3. The data of p53 mutations found in B-NHL patients are summarized in Table IV .
Overall, we found 20 p53 mutations in B-NHL/(B-ALL samples. All of these nucleotide changes detected, resulted in amino acid changes. Except for one nonsense mutation (exon 6, codon 213) in the LN of B-NHL patient 4, all 20 mutations found were missense mutations. Two p53 mutations were homozygous, both found in B-NHL-samples, and one of these patients harboured a germ line mutation. The mutations in codons 132, 141, 143, 155, 175, 181, 236, 238, 248 and 273 found in this investigation are all located in the DNA-binding domain of p53 (Fig. 5) . The mutations in codons 175 and 273 and the Arg-248 mutation are known to be 'contact mutations', removing essential DNA-contact residues in the DNA-binding domain of p53, resulting in substantially impaired DNA-binding in addition to stability loss. The mutation in exon 5, codon 175, found as a homozygous mutation in the LN of B-NHL patient 2, is described to cause the global denaturation of p53. For B-ALL patients, blood samples as well as BM samples taken after chemotherapy showed in each case a p53 wild-type constellation. Examples are shown in Fig. 4 , and summarized in Table III for B-ALL and in Table IV for B-NHL patients. Overall, we found the well-known C to T transition in codon 248 of exon 7, in 4 out of 11 p53 mutations in B-ALL as well as in 1 out of 9 p53 mutations in B-NHL patients. For one B-NHL patient we analysed Asc samples at the time of diagnosis as well as after relapse. While at the time of diagnosis the Asc sample was SV40-positive (100-1000 copies/500 ng DNA) and showed a homozygous p53 mutation in exon 5, the Asc sample at the time of relapse lost SV40 positivity as well as the p53 mutation. For this patient we analysed BM at the time of diagnosis and at the time of relapse as well as blood at the time of relapse. Both BM samples were SV40-positive (<100 copies/500 ng DNA) and showed wild-type p53, while the blood sample had more SV40 copies of 100-1000/500 ng DNA and had the same p53 mutation as was detected in the Asc sample at the time of diagnosis (exon 5, codon 176), although this was now heterozygous, not homozygous (Table IV) .
All specimens having a p53 mutation were SV40-positive. Therefore, our results show a significant association between SV40 positivity and p53 mutation in B-NHL/B-All samples at the time of diagnosis.
Discussion
The central role of p53 in human cancer has been exhaustively discussed and reviewed over the years. Mutations in the p53 gene correlate with cancer ethiology and molecular patho- Bt, Burkitt's type; BM-d, bone marrow at time of diagnosis; BM-th, bone marrow after chemotherapy; PBL, peripheral blood; WT, wild-type; Mut, mutation; Pos, positive; Neg, negative; Val, valine; Glut, glutamine; Arg, arginine; Cys, cysteine; Thr, threonine; Lys, lysine; Trp, tryptophan. A comparable mutation of p53 was found in our investigation in one case. According to the number of mutations found at this position in the UMD p53 database (79), all mutations, except two (codons 141 and 143) that we found in our investigation are located in codons, which harbour >100 assigned mutations, and >1000 mutations as listed for codons 248 and 273. Mutations in codons 248 and 273 are two of the six 'hot-spots', known to be most frequently associated with cancer (84). In 3 B-ALL patients, we found these mutations in codons 248 and 273 (2x), which are additionally described to be classic 'contact mutations'. These mutations remove the essential DNA contact residue Arg-273 (85) . The binding capacity of p53 to DNA is reduced about 1000-fold as a result of the 273 mutation, and therefore binding capacity is largely lost (86) . The residual binding activity of mutated 273 is too weak for normal transcriptional activity in vivo (87, 88) . The Arg-248 mutation, found in one patient, is described to affect the DNA contact of p53, resulting in substantially impaired DNA binding in addition to stability loss (86, 89) . This mutation belongs to the so called 'structural mutations' of the DNAbinding domain of p53, which are known to be essential for the overall architecture of the DNA-binding surface (85) . The p53 mutation in codon 175, found as a homozygous mutation in one B-NHL patient, is known to cause the global denaturation of the p53 gene. For B-cell lymphoma the transition from C to T and G to A is an usual event, whereas G to T transversions are uncommon (90) . In this study, we found these two transitions in 6 out of 20 cases where mutations were detected. We found only 2 G to T transversions. This is in agreement with the study of Greenblatt et al (90) .
The role of p53 in virus-associated tumours, as well as its role in virus replication, have received relatively little attention up to now. Few studies have reflected on this topic, and only in cell culture experiments. The data presented in this study are based on samples derived from patients. SV40 infection leads to the formation of a stable complex between L-TAG and p53. Binding sites for p53 have been mapped to the central core of T-antigen (and E6), and these interactions are impaired by tumour-specific p53 mutations (91) . Therefore, in the case of mutated p53 in an SV40-infected cell, there is a double effect that could render the cell to tumorigenesis: SV40 L-TAG binding and inactivating of wild-type p53 and additionally p53 mutation, both hamper the apoptotic way of the cell.
The role of SV40 in the induction of B-cell malignancies, analysed in this study, as well as its possible interaction with p53, wild-type or mutated, are far from being understood. In this study, we show some interesting SV40-p53 constellations. Sixteen out of 19 B-ALL patients showed SV40 positivity at the time of diagnosis, while 10 out of these 19 patients showed a p53 mutation as well. After chemotherapy, the mutated p53 signal was lost in all 16 SV40-positive B-ALL patients, whereas they remained positive in respect to SV40, thus indicating that the leukemic clone harbours the p53 mutation. In contrast, SV40 positivity persisted, which may be interpreted as follows: Normal BM cells of these patients also harbour SV40. Whether individual leukemic cells are SV40-positive is not clear and cannot be answered until SV40 and p53 are analysed on a single cell basis. The simultaneous existence of SV40 and mutated p53 is presumably more likely to occur in LNs, as demonstrated in this study (Table IV, patients 2 and 4) . Nevertheless, the high SV40 copy number combined with mutated p53 in LNs, containing a high blast percentage, maybe a hint, that SV40 and mutated p53 act together in the same cell. However, the results obtained from the tissue samples of B-NHL patient 3 are not easy to explain. In B-NHL patient samples where p53 mutation co-exists with SV40, we detected a high copy number of SV40 (1000 copies of SV40 per 500 ng DNA). This could be demonstrated for LNs as well as for Ascs at the time of diagnosis. Moreover, the LNs of patients 1 and 4 (Table IV) showed 2 (patient 1) and 3 (patient 4) different p53 mutations. In 2 SV40-positive B-NHL patients, p53 mutation was even homozygous at the time of diagnosis. In the case of the p53 wild-type constellation, the SV40 copy number was very low (<100 copies per 500 ng DNA) or negative.
In the case of p53 mutation one can assume that at least one mutated p53 allele exists per leukemic cell and that this is not congruent with the calculated SV40 copy number (one SV40 copy per 10 or 100 cells). In this study, we conclude that in comparison to the p53 mutation number, the SV40 copy number is low. With our approach of a simultaneous existence a cooperation of SV40 and p53 in leukemic cells cannot be proven. From our data it can be derived that normal BM (BM in remission in this study) is a reservoir of SV40 which nevertheless could be involved in the induction of B-NHL and B-ALL as well as p53 mutations. But this needs more investigation. Without more data regarding the individual leukaemia/ lymphoma cell on a single cell basis, concerning SV40 and p53 mutation, one can only presume about the cooperative transformation mechanism of these two.
A bystander effect from SV40-infected BM cells contributing to an oncogenic milieu, resulting in B-ALL induction, and p53 mutation, is possible. Therefore, SV40 infection possibly increases the oncogenic milieu of the cell, at least playing a role in controlling gene function and modulation of mutability in the case of p53 mutation. Infection with the oncogenic virus, SV40, possibly creates a local cancer milieu in the infected cell for alteration of genes e.g. the p53 gene. Cooperative oncogenic events, leading to a special local cancer milieu of the cell, have been previously described for other viruses playing a role in cancer development, e.g. for papillomaviruses (cervical neoplasia) (92) or HIV (plasma cell tumour) (93) . A milieu effect was also discussed in the pathogenesis of other malignant diseases, such as lung cancer (94) and thyroid tumorigenesis (95) .
A mechanism utilising the enzyme activated cytidine deaminase is an important player in the natural immunity against viral infections, and could lead to transforming point mutations in cellular genes, e.g. the p53 gene. The high discrepancies of SV40 and p53 copy numbers could suggest a 'hit and run' mechanism where the initial presence of SV40 was lost during the transformation mechanism. Virus-associated tumours often display point mutations in p53 (91) , as was also demonstrated in this study on childhood lymphoproliferative disorders. Therefore, the question is: Does p53 mutation represent a separate pathway to tumour development, or does viral antagonism predispose to p53 mutation?
Neil et al discuss, that in viral infections it could be necessary to suppress apoptosis caused by forced entry into the S phase (91) . However, other viral proteins could achieve this effect: Adenovirus E1B 19K suppresses most types of apoptosis. Perhaps p53 has other functions that DNA viruses, such as SV40, need to eliminate. This has to be investigated thoroughly in further investigations. In the case of B-NHL/B-ALL, as shown in this study, it is possible, that mutated p53 and SV40 can act together to render these cells more sensitive to leukemia. Carbone et al showed that p53 is not only a passive inactive partner of SV40 L-TAG, but can promote malignant cell growth. They demonstrated that the p53 L-TAG complex binds to the IGF-I gene and therefore stimulates the activation of the IGF-I pathway (96) . This demonstrates that the dogma, that SV40 L-TAG inactivates p53 function completely, has to be re-assessed.
The role of p53 in virus-associated tumours remains unclear. While in some tumours, such as cervical carcinoma, mutations of p53 occur preferentially in tumours without HPV infection (97) , we demonstrated in this study that p53 mutations are frequent in SV40-infected B-cell lymphomas as well as in B-NHLs. To the best of our knowledge, this current report is the first of its kind, investigating the prevalence of SV40 in patients with lymphomas in Germany and the most extensive study correlating the p53 mutation rate with SV40 prevalence in childhood lymphoproliferative disorders. In the case of SV40, our investigation indicates a putative viral cause for B-NHL/B-ALL development as well as in other childhood lymphoproliferative disorders, such as T-and BCP-ALL. In all tested LNs of B-NHL patients we found one or more p53 mutations, among them one homozygous and one nonsense mutation. All of these LNs were SV40-positive with 100-1000 SV40 copies in 500 ng DNA. From one patient we additionally analysed BM with wild-type p53, showing <100 SV40 copies per 500 ng DNA. Due to the high content of vital tumour cells in all LNs (71-98%) and the high copy number of SV40 in one to 3 different p53 mutations, we can conclude, that SV40 and p53 mutation occur in the same cell, promoting lymphoma development. Therefore, SV40 infection and p53 mutation could be seen as cooperative oncogenic events.
In conclusion, SV40 should be added to the list of factors playing a role in the pathogenesis of B-cell lymphoma, acting together with mutated p53 in the multistep tumorigenesis of lymphoproliferative disorders.
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